To obtain an oral tablet having a core coated with rapamycin, a surface modifier and a sugar overcoat containing sugar so as to be able to effectively administer rapamycin having immunodepression, anti-rejection, antifungal action and antiinflammatory action, preferably by itself.

A surfactant such as nonionic surfactant, e.g. Pluronic F68 (R) is used as a surface modifier for forming rapamycin dispersion used during coating in production of rapamycin oral tablet and sucrose derived from beat is used for the sugar overcoat and microcrystal cellulose or polyvinylpyrrolidone (povidone) is used as a binder. As a preferred formulation, the tablet contains (1) about 0.05-20mg rapamycin, (2) about 0.008-10mg Pluronic F68, (3) about 35-99% of sucrose final sugar overcoat weight, (4) about 0.2-1.0% of povidone final sugar overcoat weight and (5) about 0.1-3.0% of microcrystal cellulose final sugar overcoat weight.